会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明申请
    • CRYSTALLINE 1-KESTOSE AND PROCESS FOR PREPARING THE SAME
    • 晶体1-酮酶及其制备方法
    • WO1997021718A1
    • 1997-06-19
    • PCT/JP1996003618
    • 1996-12-11
    • MEIJI SEIKA KABUSHIKI KAISHANISHIZAWA, KojiMATSUMOTO, HitoshiNAKAMURA, HirofumiKAWAKAMI, TakashiNAKADA, YukoHIRAYAMA, MasaoADACHI, Takashi
    • MEIJI SEIKA KABUSHIKI KAISHA
    • C07H03/06
    • C07H3/06C12P19/18C30B7/00
    • A process for preparing crystalline 1-kestose which enables crystalline 1-kestose in large fine granulated sugar form to be prepared with high recovery. The process comprises concentrating a high-purity 1-kestose solution to a Brix of not less than 75, depositing crystallites serving as a mother nucleus by adding seed crystals or by concentration under reduced pressure, and repeating at least twice the step of growing crystals by concentration under reduced pressure and the step of redissolving crystallites produced in the concentrate. Alternatively, the process comprises concentrating a high-purity 1-kestose solution to a Brix of not less than 80, growing crystals after addition of seed crystals or induction of crystallization, and repeating at least twice the step of lowering the temperature by 5 to 20 DEG C below the temperature in the previous step and the step of growing crystals growth by allowing the concentrate to stand at the above temperature. An enzyme capable of efficiently converting sucrose to 1-kestose is also disclosed.
    • 制备结晶1-kestose的方法,其使得能够以高回收率制备大细粒状糖形式的结晶1-kestose。 该方法包括将高纯度1-kestose溶液浓缩至不小于75的白利糖度,通过加入晶种或通过减压浓缩沉积作为母核的微晶,并重复至少两次生长晶体的步骤 在减压下的浓度和再浓缩浓缩物中产生的微晶的步骤。 或者,该方法包括将高纯度1-kestose溶液浓缩至不低于80的白利糖度,加入晶种后生长晶体或诱导结晶,并重复至少两次将温度降低5至20的步骤 ℃以下,通过使浓缩物在上述温度下放置,生长晶体生长步骤。 还公开了能够有效地将蔗糖转化成1-kestose的酶。
    • 8. 发明申请
    • NOVEL TETRAHYDRONAPHTHOFURANONE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME
    • 新的四氢呋喃酮衍生物及其制备方法
    • WO1997030040A1
    • 1997-08-21
    • PCT/JP1997000451
    • 1997-02-19
    • MEIJI SEIKA KABUSHIKI KAISHAKURIHARA, KenichiSHINEI, RieTANABE, KiyoshiYAMAMOTO, YasuoAJITO, KeiichiMIYAJIMA, KaoriTABATA, YujiYASUDA, ShoheiTATSUTA, KuniakiOKONOGI, Tsuneo
    • MEIJI SEIKA KABUSHIKI KAISHA
    • C07D307/92
    • C07D307/92C07D407/12C07D407/14C07D409/12C07D417/12
    • Compounds represented by general formula (I) and pharmaceutically acceptable salts thereof, which have progesterone receptor binding inhibitory activities and so are used as remedies and preventives for diseases in which progesterone participates, more particularly, as anticancer agents against mammary and ovarian cancers, remedies for uterine myoma, endometriosis, meningioma and myeloma, abortifacient, peroral contraceptive, and remedies and preventives for osteoporosis and climacteric disturbance, wherein R and R represent each hydroxy, alkyloxy, alkenyloxy, alkynyloxy, cycloalkyloxy, alkoxyalkyloxy, oxygenous cycloalkyloxy, aralkyloxy, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, cycloalkylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, aralkylcarbonyloxy, aromatic acyloxy, heteroaromatic acyloxy, saturated heterocyclic carbonyloxy, alkylsulfonyloxy, aromatic sulfonyloxy, alkylcarbamoyloxy, or aromatic carbamoyloxy, the R optionally representing hydrogen alkyl, alkenyl, or alkynyl; and R , R , and R represent each independently hydrogen, alkyl, or alkenyl.
    • 具有孕酮受体结合抑制活性的由通式(I)表示的化合物及其药学上可接受的盐等用作对孕激素参与的疾病的补救措施和预防药物,更特别地,作为抗乳腺癌和卵巢癌的抗癌剂, 子宫肌瘤,子宫内膜异位症,脑膜瘤和骨髓瘤,流产,口服避孕药,以及骨质疏松症和更年期障碍的治疗和预防药物,其中R 1和R 2代表各羟基,烷氧基,烯氧基,炔氧基,环烷氧基,烷氧基烷氧基, 芳烷氧基,烷基羰基氧基,链烯基羰基氧基,炔基羰基氧基,环烷基羰基氧基,烷氧基羰基氧基,芳氧基羰基氧基,芳烷基羰基氧基,芳香族酰氧基,杂芳基酰氧基,饱和杂环羰基氧基,烷基磺酰氧基,芳香族磺酰氧基,烷基氨基甲酰氧基或芳族氨基甲酰氧基,R 1任选代表氢 烷基,烯基或炔基; R 3,R 4和R 5各自独立地表示氢,烷基或链烯基。